SAB Biotherapeutics (SABS) Stock Analysis & Winston Score

SAB Biotherapeutics is a biotechnology company that develops human antibody treatments using a unique platform: genetically engineered cattle. The company modifies cows so their immune systems produce large quantities of fully human antibodies, which can then be harvested and used as medicines. Its main focus is on infectious diseases and immune conditions, with potential customers including government health agencies and pharmaceutical partners. The company earns revenue primarily through government contracts and research partnerships rather than commercial drug sales, as it has no approved products on the market yet. It operates mainly in the United States and remains a small, pre-revenue clinical-stage company. Its genetically engineered cattle platform is a genuine scientific differentiator, but the core risk is significant: the company is burning cash with no approved therapies, and it must successfully advance its pipeline through clinical trials and secure regulatory approval before it can generate sustainable revenue.